Nigel Key News Today

The U.S. Food and Drug Administration (FDA) approved Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of adults with hemophilia B (congenital factor 9 deficiency) who currently use factor 9 prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

A gene therapy clinical trial for hemophilia shows promise and could be approved by the FDA later this year — a feat made possible, in part, by UNC-Chapel Hill's 70-year-old research program

What we know about the super-rare blood clots linked to the J&J vaccine Experts are figuring out how to rapidly diagnose and treat the unusual clots linked to both the Johnson & Johnson and AstraZeneca shots. ByLinda Marsa Email Scientists are beginning to unravel what is sparking the rare but severe blood clotting reaction that has now been associated with both the Johnson & Johnson and the AstraZeneca coronavirus vaccines. Called cerebral venous sinus thrombosis (CVST), this condition occurs ...

Can AstraZeneca dispel doubts about its shots? With the company caught up in murky data releases and public relations misfires, experts worry that the world may turn its back on a vaccine that still holds promise for combating the pandemic. ByLinda Marsa The AstraZeneca shot was supposed to be the vaccine for a couple of billion people. It is inexpensive at just a couple of dollars per dose and can be stored in an ordinary fridge unlike the mRNA vaccines. But after reports the shot may trigger...

Persistent Cover Crop Adoption Varies by Primary Commodity Crop The use of cover crops on U.S. cropland increased by 50 percent between 2012 and 2017. During this period, Federal and State conservation programs increased efforts to promote cover crops through financial and technical assistance. Cover crops—such as unharvested cereal rye, oats, winter wheat, or clover—are typically added to a crop rotation during the period in between two commodity or forage crops. Cover crops provide a livi...

Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials